HALLE/SAALE, Germany, 11 January 2016 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), announces, that key patents for […]
HALLE/SAALE, Germany, 05 January 2016 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company is […]
PQ912 is currently in Phase 2a studies in Alzheimer’s disease patients HALLE/SAALE, Germany, 15 December 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing […]
HALLE/SAALE, Germany, 20 November 2015 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company […]
HALLE/SAALE, Germany, 19 November 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces its […]
HALLE/SAALE, Germany, 12 November 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish its third quarter […]
NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA HALLE/SAALE, Germany, 5 November 2015 – Probiodrug AG (the “Company“) (Euronext […]
HALLE/SAALE, Germany, 28 October 2015 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that the company is scheduled […]
Presentation at the Society for Neuroscience (SfN) Annual Meeting HALLE/SAALE, Germany, 19 October 2015 – Probiodrug AG (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic […]